

## Mini Review

## ETV6 (TEL1) in Blood Cell Development and Malignancy

Parisa Rasighaemi<sup>1</sup>, Clifford Liongue<sup>1,2</sup> and Alister C Ward<sup>1,2\*</sup><sup>1</sup>School of Medicine, Deakin University, Australia<sup>2</sup>Strategic Research Centre in Molecular and Medical Research, Deakin University, Australia**\*Corresponding author:** Alister C Ward, School of Medicine, Deakin University, Pigdons Road, Geelong, Victoria 3216, Australia, Tel: 61-3 5227 2041; Fax: 61-3 5227 2945; Email: award@deakin.edu.au**Received:** September 25, 2014; **Accepted:** October 27, 2014; **Published:** October 27, 2014**Abstract**

The *ETV6* (*TEL1*) gene encodes a member of the ETS family of transcriptional regulators. It represents one of the most frequently disrupted genes in haematological malignancies, with over 50 different translocations described. Moreover, deletion, silencing or truncating mutations have also been reported, suggesting a potential tumor suppressor function. Recent studies have shown that *ETV6* plays a broad and complex role in early hematopoiesis, impacting on the development of multiple lineages, providing new insights into how its perturbation contributes to disease.

**Keywords:** ETV6; TEL1; ETS; Hematopoiesis; Leukemia**Abbreviations**

AML: Acute Myelogenous Leukemia; AEL: Acute Eosinophilic Leukemia; ALL: Acute Lymphocytic Leukemia; Bc: Blastic crisis; BP: Blastic Phase; CIM: Chronic Idiopathic Myelofibrosis; CML: Chronic Myelogenous Leukemia; CMML: Chronic Myelomonocytic Leukemia; CP: Chronic Phase; ETS: E26-Transforming Specific; ETV: ETS Variant; HDAC: Histone Deacetylase; HLH: Helix-Loop-Helix; MDS: Myelodysplastic Syndrome; MPN: Myeloproliferative Neoplasm; Ph: Philadelphia chromosome; PNT: Pointed; PV: Polycythemia Vera; RA: Refractory Anemia; RAEB: Refractory Anemia with excess of Blasts; TCL: T Cell Leukemia; TEL: Translocating E26 transforming-specific Leukemia

**Introduction**

*ETV6* (ETS variant 6) also known as *TEL1* (Translocating E26 transforming-specific leukemia 1) and the related *ETV7* or *TEL2* are members of the evolutionarily-conserved ETS (E26-transforming specific) family of transcription factors, which have been implicated in a variety of cellular development and differentiation processes [1,2]. All ETS proteins share an extensively conserved domain of about 85 amino acids, which binds to purine-rich sequences within the promoters or enhancers of target genes, utilizing a GGAA/T sequence that is flanked by 5-8 nucleotide, thus determining the specificity of each family member [3,4]. This so-called ETS domain represents a winged helix-turn-helix domain composed of 3  $\alpha$ -helices and 4  $\beta$ -sheets arranged in the order  $\alpha 1$ - $\beta 1$ - $\beta 2$ - $\alpha 2$ - $\alpha 3$ - $\beta 3$ - $\beta 4$  [5]. Another evolutionary conserved domain shared by a subset of ETS family members is the Pointed (PNT) domain, which is in the form of a modified Helix-Loop-Helix (HLH) structure for mediating protein-protein interactions [6]. Although some ETS family members are expressed ubiquitously, others are predominantly expressed in a tissue-specific manner [7], including in hematopoietic cells where they regulate blood cell development [8].

**ETV6 gene and protein structure and function**


The human *ETV6* gene spans a region of over 240 kb on the short (P) arm of chromosome 12 at band 13.1 and consists of 8 exons [9]. There are two isoforms of *ETV6* (57 kDa and 53 kDa) arising from alternative start codons in exon 1a (Figure 1) [10]. The PNT domain at its N-terminus is encoded by exons 3 and 4 and the ETS domain at

its C-terminus is encoded by exons 6 and 7 flanking a central domain encoded by exon 5 (Figure 1).

The PNT domain is responsible for homo or heterodimerization with a range of proteins, including the closely-related *ETV7* protein, the ETS family member *FLI1* and the ubiquitin-conjugating enzyme *UBC9* [6,7,11,12]. This domain is required for the repression of target genes [13], and also mediates the nuclear export of *ETV6*, thereby regulating its activity [14]. The positively charged ETS domain is responsible for binding to DNA [15,16]. The less conserved central domain contributes to the repression activity of *ETV6* [17-21].

In several studies *ETV6* has been identified as a strong transcriptional repressor [17,18]. This has been mapped to the PNT and central domains. PNT domain-mediated repression has been shown to be dependent on interaction with the SPM domain of *L3MBTL1* (human homolog of the *Drosophila* Lethal3 Malignant brain tumor protein), a member of polycomb group of chromatin-associated proteins, which stabilizes the repressive effect of *ETV6* on transcription through a HDAC (histone deacetylase) independent mechanism [22]. In contrast, repression by the central domain is mediated through binding of various co-repressors, including *SMRT*, *mSin3A*, *N-CoR* and *Tip60*, which subsequently recruit HDACs to mediate transcriptional repression [17-21].

While *ETV6* would appear to regulate the transcription of genes



**Figure 1: ETV6 chromosomal location, gene and protein structure.** Schematic representation of the *ETV6* gene locus on human chromosome 12 (upper panel), the *ETV6* gene transcript with numbered boxes corresponding to exons (middle panel), and the *ETV6* protein with domains indicated and relevant amino acids numbered (lower panel).

with ETS consensus sites in their promoters, only a handful of genes actually targeted by ETV6 are known. These include the *GPIIb* and *GPIIb $\alpha$*  genes in myeloid K562 cells induced with TPA [23], the *TCL1* (T-cell lymphoma 1) oncogene in pre-B cell acute lymphoblastic leukemia cells [24], the *BCL-XL* gene in NIH 3T3 cells [13] and  $\beta$ -globin in transgenic mice expressing human ETV6 under the control of the *Gata1* promoter [25] as well as acting on the *Stromelysin* (MMP3) promoter in Ras-transformed NIH3T3 cells [26].

### Role of ETV6 *in vivo*


ETV6 has been shown to play an important role in normal embryonic development and hematopoietic regulation. Targeted knockout of the *Etv6* gene in mice led to embryonic lethality at day 10.5-11.5 of development due to mesenchymal and neural cell apoptosis accompanied by defective angiogenesis in the yolk sac [27]. Primary erythropoiesis at this time was unaffected. However, further analysis of chimerical mice consisting of *Etv6*<sup>-/-</sup> cells and normal (*Etv6*<sup>+/+</sup>) cells revealed that although *Etv6*<sup>-/-</sup> cells contributed to yolk sac and fetal liver hematopoiesis, they were totally absent from the bone marrow. These findings revealed that *Etv6* was essential for the establishment of definitive hematopoiesis in mice [28]. Knockdown of *etv6* in *Xenopus* also revealed a requirement for this gene in the formation of the first definitive hematopoietic stem cells in the dorsal aorta [29]. Conditional knockouts in adult mice indicated that *Etv6* was essential for survival of adult HSCs within hematopoietic niches [30]. However, ablation of *Etv6* after lineage commitment did not affect adult hematopoietic except for specific maturation defects in the megakaryocytic lineage [30].

In contrast, transgenic mice expressing human *ETV6* under the control of *Gata1* promoter revealed that ETV6 was also involved in both proliferation and differentiation in the erythroid lineage, depending on the stage of erythroid development. During the early stages of erythropoiesis, ETV6 was found to accelerate proliferation, while in the latter stages it increased differentiation including stimulation of hemoglobin synthesis. The latter was achieved through indirect promotion of ALAS-E transcription and direct stimulation of  $\beta$ -globin synthesis [25]. This may explain the observation that enhanced expression of ETV6 in mouse erythroleukemia cells induced their differentiation toward erythrocytes [31]. Recent studies in zebrafish have confirmed a broad role for ETV6 in embryonic hematopoiesis, impacting on progenitor cells, as well as erythroid, myeloid and lymphoid populations [32].

### Chromosomal translocations involving ETV6 in hematological malignancy

The human *ETV6* gene is notable for its frequent involvement in chromosomal translocations associated with hematological malignancies. Approximately 50 translocations involving the *ETV6* gene have been described, involving around 30 partner genes [33]. These translocations can be classified according to the type of fusion partners namely: tyrosine kinases, transcription factors and other proteins (Figure 2).

**Tyrosine kinases:** The ETV6/tyrosine kinase fusions have been detected in a plethora of hematological malignancies. In all cases, including fusions with ABL1, ABL2, JAK2, SYK, FRK, LYN, FGFR3, PDGFRA, PDGFRB, NTRK3 and FLT3, the PNT domain of ETV6



**Figure 2: ETV6 fusion partner network.**

Graphical representation of the various proteins found fused to ETV6 in malignancy are shown by class: tyrosine kinases (blue), transcription factors (green) and other proteins (orange).

is fused to the tyrosine kinase domain of the fusion partner. In this way the PNT domain mediates dimerization of the tyrosine kinase, resulting in its constitutive activation with subsequent autophosphorylation and phosphorylation of downstream signal transducing proteins, such as STATs (Table 1). The use of animal models has revealed new insights into the function of these fusion oncoproteins, for example ETV6-JAK2 [34,35].

**Transcription factors:** ETV6/transcription factor fusions have been implicated in variety of leukemias. In these cases, the fusion modifies the transcription activity of ETV6 and/or the fusion partner by converting a transcriptional repressor into an activator or vice versa, which can be achieved in three different ways. Fusions with involvement of the PNT domain of ETV6, such as fusions with RUNX1 and ARNT, result in a dominant-negative effect of the fusion protein over the normal function of the fusion partner. However, in fusions that involve both PNT and ETS domains of ETV6, such as fusions with MN1, PAX5 and HLBX9, the chimeric protein appears to act as an aberrant transcription factor and results in modification of both ETV6 and partner protein transcription activity. Finally, in fusions that involve the promoter – rather than a functional domain – of ETV6, such as with EVI1 and CDX2, ectopic expression of the fusion partner genes in hematopoietic cells has been suggested to mediate leukemogenesis (Table 2).

**Other proteins:** Other ETV6 translocations not involving tyrosine kinases or transcription factors have been reported in variety of leukemias. In most of these cases, just the first two exons of ETV6 are involved in the translocation. It is believed that in these cases, involving fusions to CHIC2, MDS2, TTL, STL, ACS2 and PER1, the over expression of a neighboring gene is the critical pathogenic mechanism of the translocation (Table 3).

### Tumor suppressor function of ETV6

Besides being involved in a vast number of translocations associated with hematological malignancies, there are other studies supporting the notion that ETV6 functions as a tumor suppressor gene. The short arm of chromosome 12 is a hot spot for chromosomal abnormalities in various hematological malignancies, these include interstitial deletions that lead to the loss of genetic material from 12p

**Table 1:** Tyrosine kinase fusions with ETV6.

Summary of the ETV6 fusions with tyrosine kinases, indicating the disease, translocation, ETV6 breakpoint, ETV6 domain involvement (PNT, ETS), functional mechanisms and references.

Fusion gene	Disease	Translocation	Breakpoint in ETV6	PNT	ETS	Functional mechanisms	References
ETV6-ABL1	AML, B-cell ALL, T-cell ALL, MPN, CML (Ph negative) in CP and BP	t(9;12)	int 4 or 5	+	-	• Constitutive activation of PTK domain of ABL1	[45-49]
ETV6-ABL2	AML-M4, M3, T-cell ALL	t(1;12)	int 5	+	-	• Constitutive activation of PTK domain of ABL2	[50-52]
ETV6-JAK2	Pre-B cell ALL, aCML, T-cell ALL	t(9;12)	int 4 or 5	+	-	• Constitutive activation of PTK domain of JAK2	[53,54]
ETV6-FGFR3	Peripheral T-cell lymphoma	t(4;12)	int 5	+	-	• Constitutive activation of PTK domain of FGFR3	[55]
ETV6-SYK	MDS	t(9;12)	int 5	+	-	• Constitutive activation of PTK domain of SYK	[56]
ETV6-FRK	AML-M4	t(6;12)	int 4	+	-	• Constitutive activation of PTK domain of FRK	[57]
ETV6-LYN	Primary myelofibrosis	Ins(12;8)	int 5	+	-	• Constitutive activation of PTK domain of LYN	[58]
ETV6-PDGFRB	MPN	t(4;12)	int 6	+	-	• Constitutive activation of PTK domain of PDGFRB	[59]
ETV6-PDGFRB	CMML, AML-M0 on CIM, AML-M2, aCML in Bc	t(5;12)	int 4 or 7	+	-	• Constitutive activation of PTK domain of PDGFRB	[59-62]
ETV6-NTRK3	AML-M2, M0, CEL	t(12;15)	int 4 or 5	+	-	• Constitutive activation of PTK domain of NTRK3	[63-65]
ETV6-FLT3	MPN with hypereosinophilia, T-lymphoblastic lymphoma	t(12;13)	int 4 or 5	+	-	• Constitutive activation of PTK domain of FLT3	[66,67]

AML: Acute Myelogenous Leukemia; ALL: Acute Lymphocytic Leukemia; MPN: Myeloproliferative Neoplasm; CML: Chronic Myelogenous Leukemia; Ph: Philadelphia chromosome; CP: Chronic Phase; BP: Blastic Phase; aCML: atypical CML; MDS: Myelodysplastic Syndrome; CMML: Chronic Myelomonocytic Leukemia; CIM: Chronic Idiopathic Myelofibrosis; Bc: Blastic crisis; CEL: Chronic Eosinophilic Leukemia

**Table 2:** Transcription factor fusion partners of ETV6.

Summary of the ETV6 fusions with other transcription factors, as detailed in Table 1.

Fusion gene	Disease	Translocation	Breakpoint in ETV6	PNT	ETS	Functional mechanisms	References
ETV6-RUNX1	B-cell ALL	t(12;21)	int 4 or 5	+	-	• Dominant negative effect of the fusion protein over wild type ETV6 allele • Repression of RUNX1 target genes	[37,68,69]
MN1-ETV6	AML-M0, M2, M4, CML, RAEB, AML on MDS	t(12;22)	int 2 or 3	+	+	• Activation of ETV6 target genes • Repression of retinoic acid mediated transcription	[70-76]
ETV6-ARNT	AML-M2, T-cell ALL	t(1;12)	int 4	+	-	• Dominant negative effect of the fusion protein over wild type ETV6 allele • Modification of ARNT into a transcriptional repressor	[77,78]
ETV6-EV11	aCML, Bc-CML, RAEB, AML-M0	t(3;12)	int 2	-	-	• Ectopic expression of EV11	[53,79,80]
ETV6-CDX2	AML-M1	t(12;13)	int 2	-	-	• Ectopic expression of CDX2	[50,81]
PAX5-ETV6	B-cell ALL	t(9;12)	int 2	+	+	• Modification of ETV6 and/or PAX5 transcription activity	[82,83]
HLXB9-ETV6	AML-M0, M1, M2, M3, M7	t(7;12)	int 2	+	+	• Modification of ETV6 and/or HLXB9 transcription activity?	[84-87]

ALL: Acute Lymphocytic Leukemia; AML: Acute Myelogenous Leukemia; RAEB: Refractory Anemia with Excess of Blasts; MDS: Myelodysplastic Syndrome; aCML: atypical Chronic Myelogenous Leukemia; Bc-CML: Blastic Crisis of CML

which has been mapped to a small locus containing the *ETV6* and *KIP1* genes [36]. In many cases of childhood ALL carrying t(12;21) the wild-type *ETV6* allele is deleted [9,37,38]. Interestingly, in cells harboring these translocations, consistent loss of *ETV6* expression was observed even in the absence of detectable *ETV6* deletion, suggesting that secondary structural abnormalities and epigenetic modifications may lead to the silencing of *ETV6* alleles [38]. Frequent point mutations of *ETV6* have been reported in T-ALL and AML leading to truncated forms of *ETV6* which exerted a dominant-negative effect to abolish wild type *ETV6* function [39-41]. Furthermore, in several cases of leukemia including *ETV6* translocations, neither functional fusion protein was identified nor was ectopic expression of a neighboring proto-oncogene reported. In these cases, haploinsufficiency of *ETV6*

has been raised as a contributing factor in the etiology of leukemia [42,43].

Additional evidence of a potential tumor suppressor role for *ETV6* comes from its functional studies. A transient increase in endogenous *ETV6* expression was also reported during the first 3 days of differentiation of Mouse Erythroleukemia (MEL) cells [31]. Over-expression of *ETV6* in these cells enhanced erythroid differentiation while introduction of a dominant-negative mutant of *ETV6* completely blocked this process with cells continuing to proliferate. Enforced expression of *ETV6* inhibited cell growth in Ras-transformed cells [26] and retarded proliferation of both primary wild type and immortalized cells possibly through inducing G1 arrest [44] or decreasing survival via direct repression of the Bcl-X<sub>L</sub> promoter

**Table 3:** Other protein fusion partners of ETV6. Summary of ETV6 fusions with other proteins as detailed in Table 1.

Fusion gene	Disease	Translocation	Breakpoint in ETV6	PNT	ETS	Functional mechanisms	References
CHIC2-ETV6	AML-M0,M1,M2, M/NK cell leukemia, RAEB	t(4;12)	int 1 or 2	-	-	• Overexpression of adjacent gene (GSX2)	[88-92]
ETV6-MDS2	RAEB	t(1;12)	int 2	-	-	• Overexpression of adjacent gene (PRL11)	[89]
ETV6-TTL or TTL-ETV6	Pre B-cell ALL	t(12;13)	int 1	- +	- +	• Loss of function of ETV6 or/and TTL • Overexpression of adjacent genes (p27 and FOXO1A)?	[93]
ETV6-STL or STL-ETV6-S or STL-ETV6-L, M	Pre-B ALL	t(6;12)	int 2	- + -	- + -	• Deregulation of adjacent gene (OSTL*) • Loss of ETV6 function	[94]
ETV6-PER1	AML on CMML	t(12;17)	int 1	-	-	• Overexpression of adjacent gene (HES7 or STK12)	[95]
ETV6-ACS2	RAEB, MDS, AML, AEL, PV, CML	t(5;12)	int 1 or 2	-	-	• Overexpression of adjacent gene (IL-3)	[89,96-99]
ETV6-PTPRR	AML-M2	inv(12)	int 4	+	-	• Dominant negative effect of the fusion protein over wild type ETV6 allele • Constitutive activation of ETV6 target genes	[100]
ETV6-NCOA2	AML-M2, ALL	t(8;12)	int 4 or 5	+	-	• Modification of transcriptional activity of CBP-dependent activators • Haploinsufficiency of ETV6 and/or BAZ2A?	[101]
ETV6-BAZ2A	Pre B-cell ALL	t(12;12)	int 2	-	-	• Deregulation of BAZ2A or a gene in vicinity of BAZ2A?	[43]
ETV6-GOT1	RA, RAEB	t(10;12)	int 2 or 3	-	-	• Dominant negative effect of fusion protein over both GOT and ETV6	[102,103]
ETV6-FCHO2	AML-M1	t(5;12;22)	int 2	-	-	• Haploinsufficiency of ETV6 and/or FCHO2	[42]
ETV6-IGH	Pre B-cell ALL	t(12;14)	?	?	?	?	[104]

AML: Acute Myelogenous Leukemia, RAEB: Refractory Anemia with Excess of Blasts, ALL: Acute Lymphocytic Leukemia, CMML: Chronic Myelomonocytic Leukemia, MDS: Myelodysplastic Syndrome, AEL: Acute Eosinophilic Leukemia, PV: Polycythemia Vera, CML: Chronic Myelogenous Leukemia, RA: Refractory Anemia, RAEB: Refractory Anemia with Excess of Blasts.

\*OSTL (or opposite STL) shares the first exon with STL but is transcribed in the opposite direction.

[13]. It has also been demonstrated that ETV6 over expression slowed the Ras-induced tumor formation in nude mice [44].

## Conclusion

ETV6 remains best known for its role as a hot spot for translocation, yielding a large number of chromosomal fusions important in the etiology of hematological malignancy. However, more recent studies have indicated that the encoded protein is both a tumor suppressor and an important regulator of hematopoiesis, which provides new insights into how its disruption contributes to malignancy. Key questions remaining for future research are, firstly, which genes are targeted by ETV6 in both its tumor suppressor and oncogenic roles and, secondly, whether pharmacologic agents can be developed to either enhance the former or hinder the latter.

## Acknowledgment

The work was supported by funding from Deakin University via an International Postgraduate Research Scholarship (to PR) and an Alfred Deakin Postdoctoral Research Fellowship (to CL). The authors have no conflicts of interest to declare.

## References

- Dittmer J, Nordheim A. Ets transcription factors and human disease. *Biochim Biophys Acta*. 1998; 1377: F1-11.
- Sharrocks AD, Brown AL, Ling Y, Yates PR. The ETS-domain transcription factor family. *Int J Biochem Cell Biol*. 1997; 29: 1371-1387.
- Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. *Adv Cancer Res*. 1998; 75: 1-55.
- Janknecht R, Nordheim A. Gene regulation by Ets proteins. *Biochim Biophys Acta*. 1993; 1155: 346-356.
- Kodandapani R, Pio F, Ni CZ, Piccialli G, Klemsz M, McKercher S, et al. A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex. *Nature*. 1996; 380: 456-460.
- Kim CA, Phillips ML, Kim W, Gingery M, Tran HH, Robinson MA, et al. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional repression. *EMBO J*. 2001; 20: 4173-4182.
- Potter MD, Buijs A, Kreider B, van Rompaey L, Grosveld GC. Identification and characterization of a new human ETS-family transcription factor, TEL2, that is expressed in hematopoietic tissues and can associate with TEL1/ETV6. *Blood*. 2000; 95: 3341-3348.
- Bassuk AG, Leiden JM. The role of Ets transcription factors in the development and function of the mammalian immune system. *Adv Immunol*. 1997; 64: 65-104.
- Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, et al. The 12; 21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. *Blood*. 1996; 87: 2891-2899.
- Baens M, Peeters P, Guo C, Aerssens J, Marynen P. Genomic organization of TEL: the human ETS-variant gene 6. *Genome Res*. 1996; 6: 404-413.
- Chakrabarti SR, Sood R, Ganguly S, Bohlander S, Shen Z, Nucifora G. Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. *Proc Natl Acad Sci U S A*. 1999; 96: 7467-7472.
- Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, et al. The t(12;21) translocation converts AML-1B from an activator to a repressor of transcription. *Mol Cell Biol*. 1996; 16: 1349-1355.
- Irvin BJ, Wood LD, Wang L, Fenrick R, Sansam CG, Packham G, et al. TEL, a putative tumor suppressor, induces apoptosis and represses transcription

- of Bcl-XL. *J Biol Chem*. 2003; 278: 46378-46386.
14. Wood LD, Irvin BJ, Nucifora G, Luce KS, Hiebert SW. Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor. *Proc Natl Acad Sci USA*. 2003; 100: 3257-3262.
  15. Poirel H, Oury C, Carron C, Duprez E, Laabi Y, Tsapis A, et al. The TEL gene products: nuclear phosphoproteins with DNA binding properties. *Oncogene*. 1997; 14: 349-357.
  16. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. *Gene*. 2003; 303: 11-34.
  17. Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J. TEL is a sequence-specific transcriptional repressor. *J Biol Chem*. 1999; 274: 30132-30138.
  18. Chakrabarti SR, Nucifora G. The leukemia-associated gene TEL encodes a transcription repressor which associates with SMRT and mSin3A. *Biochem Biophys Res Commun*. 1999; 264: 871-877.
  19. Guidez F, Petrie K, Ford AM, Lu H, Bennett CA, MacGregor A, et al. Recruitment of the nuclear receptor corepressor N-CoR by the TEL moiety of the childhood leukemia-associated TEL-AML1 oncoprotein. *Blood*. 2000; 96: 2557-2561.
  20. Wang L, Hiebert SW. TEL contacts multiple co-repressors and specifically associates with histone deacetylase-3. *Oncogene*. 2001; 20: 3716-3725.
  21. Nordentoft I, Jorgensen P. The acetyltransferase 60 kDa trans-acting regulatory protein of HIV type 1-interacting protein (Tip60) interacts with the translocation E26 transforming-specific leukaemia gene (TEL) and function as a transcriptional co-repressor. *Biochem J*. 2003; 374: 165-173.
  22. Boccuni P, MacGrogan D, Scandura JM, Nimer SD. The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6). *J Biol Chem*. 2003; 278: 15412-15420.
  23. Sakurai T, Yamada T, Kihara-Negishi F, Teramoto S, Sato Y, Izawa T, et al. Effects of overexpression of the Ets family transcription factor TEL on cell growth and differentiation of K562 cells. *Int J Oncol*. 2003; 22: 1327-1333.
  24. Fears S, Chakrabarti SR, Nucifora G, Rowley JD. Differential expression of TCL1 during pre-B-cell acute lymphoblastic leukemia progression. *Cancer Genet Cytogenet*. 2002; 135: 110-119.
  25. Eguchi-Ishimae M, Eguchi M, Maki K, Porcher C, Shimizu R, Yamamoto M, et al. Leukemia-related transcription factor TEL/ETV6 expands erythroid precursors and stimulates hemoglobin synthesis. *Cancer Sci*. 2009; 100: 689-697.
  26. Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels J, et al. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. *Mol Cell Biol*. 2000; 20: 5828-5839.
  27. Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. *EMBO J*. 1997; 16: 4374-4383.
  28. Wang LC, Swat W, Fujiwara Y, Davidson L, Visvader J, Kuo F, et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. *Genes Dev*. 1998; 12: 2392-2402.
  29. Ciau-Uitz A, Pinheiro P, Gupta R, Enver T, Patient R. Tel1/ETV6 specifies blood stem cells through the agency of VEGF signaling. *Dev Cell*. 2010; 18: 569-578.
  30. Hock H, Meade E, Medeiros S, Schindler JW, Valk PJ, Fujiwara Y, et al. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. *Genes Dev*. 2004; 18: 2336-2341.
  31. Waga K, Nakamura Y, Maki K, Arai H, Yamagata T, Sasaki K, et al. Leukemia-related transcription factor TEL accelerates differentiation of Friend erythroleukemia cells. *Oncogene*. 2003; 22: 59-68.
  32. Rasighaemi P, Onnebo SM, Liongue C, Ward AC. ETV6 (TEL1 Epub Oct 3) regulates embryonic hematopoiesis in zebrafish. *Haematologica*. 2014;.
  33. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. ETV6 fusion genes in hematological malignancies: a review. *Leuk Res*. 2012; 36: 945-961.
  34. Dos Santos NR, Ghysdael J. A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia. *Leukemia*. 2006; 20: 182-185.
  35. Onnebo SM, Rasighaemi P, Kumar J, Liongue C, Ward AC. Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish. *Haematologica*. 2012; 97: 1895-1903.
  36. Wlodarska I, Marynen P, La Starza R, Mecucci C, Van den Berghe H. The ETV6, CDKN1B and D12S178 loci are involved in a segment commonly deleted in various 12p aberration in different hematological malignancies. *Cytogenet Cell Genet*. 1996; 72: 229-235.
  37. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, et al. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. *Proc Natl Acad Sci U S A*. 1995; 92: 4917-4921.
  38. Patel N, Goff LK, Clark T, Ford AM, Foot N, Lillington D, et al. Expression profile of wild-type ETV6 in childhood acute leukaemia. *Br J Haematol*. 2003; 122: 94-98.
  39. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger D, de Knegt Y, Tang M, Lowenberg B, Delwel R. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia. *Oncogene*. 2005; 24: 4129-4137.
  40. Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, et al. ETV6 mutations in early immature human T cell leukemias. *J Exp Med*. 2011; 208: 2571-2579.
  41. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*. 2011; 118: 3080-3087.
  42. Belloni E, Trubia M, Mancini M, Derme V, Nanni M, Lahortiga I, et al. A new complex rearrangement involving the ETV6, LOC115548, and MN1 genes in a case of acute myeloid leukemia. *Genes Chromosomes Cancer*. 2004; 41: 272-277.
  43. Panagopoulos I, Strombeck B, Isaksson M, Heldrup J, Olofsson T, Johansson B. Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. *Br J Haematol*. 2006; 133: 270-275.
  44. Rompaey LV, Potter M, Adams C, Grosveld G. Tel induces a G1 arrest and suppresses Ras-induced transformation. *Oncogene*. 2000; 19: 5244-5250.
  45. Golub TR, McLean T, Stegmaier K, Carroll M, Tomasson M, Gilliland DG. The TEL gene and human leukemia. *Biochim Biophys Acta*. 1996; 1288: M7-10.
  46. La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, et al. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. *Haematologica*. 2002; 87: 789-794.
  47. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. *Cancer Res*. 1995; 55: 34-38.
  48. Malone A, Langabeer S, O'Marcaigh A, Storey L, Bacon CL, Smith OP. A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia. *Br J Haematol*. 2010; 151: 101-102.
  49. Van Limbergen H, Beverloo HB, van Drunen E, Janssens A, Hahlen K, Poppe B, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. *Genes Chromosomes Cancer*. 2001; 30: 274-282.
  50. Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J, et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). *Blood*. 1999; 93: 1025-1031.
  51. Inukai T, Sugita K, Mitsui K, Iijima K, Goi K, Tezuka T, et al. Participation of granulocyte colony-stimulating factor in the growth regulation of leukemia cells from Philadelphia chromosome-positive acute leukemia and blast crisis of chronic myeloid leukemia. *Leukemia*. 2000; 14: 1386-1395.

52. Griesinger F, Janke A, Podleschny M, Bohlander SK. Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line. *Br J Haematol.* 2002; 119: 454-458.
53. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. *Blood.* 1997; 90: 2535-2540.
54. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. *Science.* 1997; 278: 1309-1312.
55. Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. *Cancer Res.* 2001; 61: 8371-8374.
56. Li Y, Okuno Y, Zhang P, Radomska HS, Chen H, Iwasaki H, et al. Regulation of the PU.1 gene by distal elements. *Blood.* 2001; 98: 2958-2965.
57. Hosoya N, Qiao Y, Hangaishi A, Wang L, Nannya Y, Sanada M, et al. Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6; 12)(q21; p13) translocation. *Genes Chromosomes Cancer.* 2005; 42: 269-279.
58. Tanaka H, Takeuchi M, Takeda Y, Sakai S, Abe D, Ohwada C, et al. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. *Leukemia.* 2010; 24: 197-200.
59. Curtis C, Grand F, Waghorn K, Sahoo T, George J, Cross N. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease. *Leukemia.* 2007; 21: 1839-1841.
60. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell.* 1994; 77: 307-316.
61. Tokita T, Maesawa C, Kimura T, Kotani K, Takahashi K, Akasaka T, et al. Methylation status of the SOCS3 gene in human malignant melanomas. *Int J Oncol.* 2007; 30: 689-694.
62. Yahata N, Ohyashiki K, Ohyashiki JH, Kimura Y, Miyazawa K, Kodama A, et al. Late appearance of t(5;12)(q31;p12) in acute myeloid leukemia associated with eosinophilia. *Cancer Genet Cytogenet.* 1998; 107: 147-150.
63. Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). *Blood.* 1999; 93: 1355-1363.
64. Kralik JM, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. *Diagn Pathol.* 2011; 6: 19.
65. Forghieri F, Morselli M, Potenza L, Maccaferri M, Pedrazzi L, Paolini A, et al. Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma. *Eur J Haematol.* 2011; 86: 352-355.
66. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. *J Biol Chem.* 2006; 281: 1612-1619.
67. Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N, et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. *Blood.* 2011; 118: 2239-2242.
68. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. *Blood.* 1995; 85: 3662-3670.
69. Zaliova M, Meyer C, Cario G, Vaskova M, Marschalek R, Sary J, et al. TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases. *Pediatr Blood Cancer.* 2011; 56: 217-225.
70. Buijs A, Sherr S, van Baal S, van Bezouw S, van der Plas D, Geurts van Kessel A, et al. Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. *Oncogene.* 1995; 10: 1511-1519.
71. Nakazato H, Shiozaki H, Zhou M, Nakatsu M, Motoji T, Mizoguchi H, et al. TEL/MN1 fusion in a de novo acute myeloid leukaemia-M2 patient who showed strong resistance to treatment. *Br J Haematol.* 2001; 113: 1079-1081.
72. Chen S, Xue Y, Zhu X, Wu Y, Pan J. Minimally differentiated acute myeloid leukemia with t (12; 22)(p13; q11) translocation showing primary multidrug resistance and expressing multiple multidrug-resistant proteins. *Acta Haematologica.* 2007; 118: 38-41.
73. Nofrini V, Berchicci L, La Starza R, Gorello P, Di Giacomo D, Arcioni F, et al. MN1-ETV6 fusion gene arising from MDS with 5q-. *Leuk Res.* 2011; 35: e123-126.
74. Van Wely K, Meester-Smoor M, Janssen M, Aarnoudse A, Grosveld G, Zwarthoff E. The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on RAR-RXR-mediated transcription. *Oncogene.* 2007; 26: 5733-5740.
75. Buijs A, van Rompaey L, Molijn AC, Davis JN, Vertegaal AC, Potter MD, et al. The MN1-TEL fusion protein, encoded by the translocation (12;22) (p13;q11) in myeloid leukemia, is a transcription factor with transforming activity. *Mol Cell Biol.* 2000; 20: 9281-9293.
76. van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, Hellemons A, et al. The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription. *Oncogene.* 2003; 22: 699-709.
77. Salomon-Nguyen F, Della-Valle V, Mauchauffe M, Busson-Le Coniat M, Ghysdael J, Berger R, et al. The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. *Proc Natl Acad Sci U S A.* 2000; 97: 6757-6762.
78. Otsubo K, Kanegane H, Eguchi M, Eguchi-Ishimae M, Tamura K, Nomura K, et al. ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. *Cancer Genet Cytogenet.* 2010; 202: 22-26.
79. Nishimura Y, Wada H, Mori A, Takatsuka H, Tamura A, Fujimori Y, et al. Detection of ETV6/MDS1/Evi-1 chimeric transcripts in a patient with acute myelocytic leukemia and t(3;12)(q26;p13) *Int J Hematol.* 2000; 72: 108-109.
80. Tsuruyama T, Nakamura T, Jin G, Ozeki M, Yamada Y, Hiai H. Constitutive activation of Stat5a by retrovirus integration in early pre-B lymphomas of SL/Kh strain mice. *Proc Natl Acad Sci U S A.* 2002; 99: 8253-8258.
81. Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, Humphries RK, et al. Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia. *Proc Natl Acad Sci U S A.* 2004; 101: 817-822.
82. Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. *Cancer Res.* 2001; 61: 4666-4670.
83. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA. PAX5/ETV6 fusion defines cytogenetic entity dic(9;12)(p13;p13). *Leukemia.* 2003; 17: 1121-1123.
84. Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A, et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). *Cancer Res.* 2001; 61: 5374-5377.
85. von Bergh AR, van Drunen E, van Wering ER, van Zutven LJ, Hainmann I, Lonnerholm G, et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. *Genes Chromosomes Cancer.* 2006; 45: 731-739.
86. Hauer J, Tosi S, Schuster FR, Harbott J, Kolb HJ, Borkhardt A. Graft versus leukemia effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 rearrangement. *Pediatr Blood Cancer.* 2008; 50: 921-923.
87. Taketani T, Taki T, Sako M, Ishii T, Yamaguchi S, Hayashi Y. MNX1-ETV6 fusion gene in an acute megakaryoblastic leukemia and expression of the

- MNX1 gene in leukemia and normal B cell lines. *Cancer Genet Cytogenet.* 2008; 186: 115-119.
88. Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P, et al. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with a t(4;12)(q11-q12;p13). *Blood.* 1999; 94: 1820-1824.
89. Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M, et al. Evidence for position effects as a variant ETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) ort(5;12)(q31;p31). *Blood.* 2002; 99: 1776-1784.
90. Kuchenbauer F, Schoch C, Holler E, Haferlach T, Hiddemann W, Schnittger S. A rare case of acute myeloid leukemia with a CHIC2-ETV6 fusion and multiple other molecular aberrations. *Leukemia.* 2005; 19: 2366-2368.
91. Chen B, Zhao W, Jin J, Xue Y, Cheng X, Chen X, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. *Leukemia.* 2005; 19: 767-775.
92. Silva FP, Morolli B, Storlazzi CT, Zagaria A, Impera L, Klein B, et al. ETV6 mutations and loss in AML-M0. *Leukemia.* 2008; 22: 1639-1643.
93. Qiao Y, Ogawa S, Hangaishi A, Yuji K, Izutsu K, Kunisato A, et al. Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q14), and its implication in leukemogenesis. *Leukemia.* 2003; 17: 1112-1120.
94. Suto Y, Sato Y, Smith SD, Rowley JD, Bohlander SK. A t(6;12)(q23;p13) results in the fusion of ETV6 to a novel gene, STL, in a B-cell ALL cell line. *Genes Chromosomes Cancer.* 1997; 18: 254-268.
95. Penas EMM, Cools J, Algenstaedt P, Hinz K, Seeger D, Schafhausen P, et al. A novel cryptic translocation t(12; 17)(p13; p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene. *Genes Chromosomes Cancer.* 2003; 37: 79-83.
96. Katsura Y, Suzukawa K, Nanmoku T, Nemoto N, Machino T, Obara N, et al. Myelodysplastic syndrome accompanied by basophilia and eosinophilia with t(5;12)(q31;p13). *Cancer Genet Cytogenet.* 2007; 178: 85-88.
97. Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto S, et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). *Genes Chromosomes Cancer.* 1999; 26: 192-202.
98. Murati A, Adelaide J, Gelsi-Boyer V, Etienne A, Remy V, Fezoui H, et al. t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera. *Leukemia.* 2006; 20: 1175-1178.
99. Erben P, Gosenca D, Muller MC, Reinhard J, Score J, Del Valle F, et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. *Haematologica.* 2010; 95: 738-744.
100. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. *Arthritis Res Ther.* 2005; 7: 100-110.
101. Strehl S, Nebral K, Konig M, Harbott J, Strobl H, Ratei R, et al. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. *Clin Cancer Res.* 2008; 14: 977-983.
102. Vidarsdottir S, Walenkamp MJ, Pereira AM, Karperien M, van Doorn J, van Duyvenvoorde HA, et al. Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. *J Clin Endocrinol Metab.* 2006; 91: 3482-3485.
103. Struski S, Mauvieux L, Gervais C, Helias C, Liu KL, Lessard M. ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome. *Haematologica.* 2008; 93: 467-468.
104. Lu XY, Harris CP, Cooley L, Margolin J, Steuber PC, Sheldon M, et al. The utility of spectral karyotyping in the cytogenetic analysis of newly diagnosed pediatric acute lymphoblastic leukemia. *Leukemia.* 2002; 16: 2222-2227.